Showing 2131-2140 of 3223 results for "".
- ELT Sight Acquires Assets and IP of MLase AG Excimer Ophthalmic Laser System for Glaucoma Surgeryhttps://modernod.com/news/elt-sight-acquires-assets-and-ip-of-mlase-ag-excimer-ophthalmic-laser-system-for-glaucoma-surgery/2477086/ELT Sight announced the company has acquired the IP and assets of MLase AG’s excimer ophthalmic laser system for glaucoma surgery. Terms for the acquisition were not disclosed. MLase manufactures and markets laser systems, including the ExTra ELT Laser and disposable applicator used
- Bloomberg: Allergan CEO’s Best Career Decision Was Taking a ‘Huge’ Pay Cuthttps://modernod.com/news/bloomberg-allergan-ceos-best-career-decision-was-taking-a-huge-pay-cut/2477083/Allergan Chief Executive Officer Brent Saunders told Bloomberg News that one of the most important career moves he ev
- Allergan Issues Recall for Certain Lots of Xen 45https://modernod.com/news/allergan-issues-recall-for-certain-lots-of-xen-45/2477061/Allergan has initiated a voluntary recall of its XEN 45 glaucoma drainage device after a small number of units in an unreleased lot were observed to have trace amounts of polishing compounds that are used in the needle sleeve manufacturing process, according to a joint news release with ASCRS.
- Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-releases-expanded-results-from-allergen-chamber-trial-and-announces-plans-to-initiate-the-phase-3-invigorate-trial-in-patients-with-allergic-conjunctivitis/2477060/Aldeyra Therapeutics announced expanded results from the company’s allergen chamber clinical methods trial of topical ocular reproxalap in patients with allergic conjunctivitis, and phase 3 clinical trial plans based on recent feedback from the FDA. “The expanded results from our allergen
- Julia A. Haller, MD, Elected to National Academy of Medicinehttps://modernod.com/news/julia-a-haller-md-elected-to-national-academy-of-medicine/2477033/Wills Eye Hospital announced its Ophthalmologist-in-Chief, Julia A. Haller, MD, has been elected to the National Academy of Medicine (NAM), considered one of the highest honors in the fields of health and medicine, recognizing individuals who have demonstrated outstanding professional achievement
- Alcon Contact Lens and Cataract Innovations to Headline Clinical and Educational Program at #Academy19https://modernod.com/news/alcon-contact-lens-and-cataract-innovations-to-headline-clinical-and-educational-program-at-academy19/2477022/Alcon will bring major contact lens and cataract innovations together for the first time at the 2019 American Academy of Optometry (AAO / #Academy19) meeting taking place October 23-27 at the Orange County Convention Center (OCCC) in Orlando, according to a company news release. Innovations like
- Aerpio Pharmaceuticals Announces Review of Strategic Alternativeshttps://modernod.com/news/aerpio-pharmaceuticals-announces-review-of-strategic-alternatives/2477023/Aerpio Pharmaceuticals announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the company’s clinical assets and cash resources, which amounted to $48.2 million as of June 30, 2019. The Boar
- Alcon Announces Findings from IRIS Registry Analyses on Real-World Cataract Patients at AAOhttps://modernod.com/news/alcon-announces-findings-from-iris-registry-analyses-on-real-world-cataract-patients-at-aao/2477012/Alcon announced findings from the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) that support the clinical value of the AcrySof platform. The IRIS Registry was used to assess characteristics and complications of IOL implantation after cataract surgery, according t
- Allergan Shareholders Approve Proposed Acquisition by AbbViehttps://modernod.com/news/allergan-shareholders-approve-proposed-acquisition-by-abbvie/2477010/Allergan announced that its shareholders have voted to approve the previously announced proposed acquisition of Allergan by AbbVie. More than 99 percent of the votes cast at both a special court-ordered meeting of shareholders and at an extraordinary general meeting of shareholders were in favor
- Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-present-late-breaking-data-from-phase-3-studies-of-investigational-abicipar-pegol-in-wet-amd/2476996/Allergan and Molecular Partners announced 2-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with wet age-related macular degeneration (AMD). In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains c